ADPKD
59 programs · 58 companies
Programs
59
Companies
58
Trials
66
MOAs
36
JAK1/2iEGFRiUSP1iALKiGLP-1agEZH2iBETiSHP2iCDK4/6iBCMA ADC
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| VRT-9481 | Phase 1/2 | Menin | ||
| Bemaderotide | Phase 3 | BCL-2 | ||
| ITO-535 | NDA/BLA | MDM2 | ||
| SLR-5251 | Phase 3 | KRASG12D | ||
| Talainavolisib | Approved | KIF18A | ||
| PEK-IIT-463 | Preclinical | WEE1 | ||
| DUK-IIT-841 | Phase 1 | C5 | ||
| AVX-9264 | Phase 2/3 | CD20 | ||
| CRV-1020 | Approved | CDK4/6 | ||
| Tixaglumide | Preclinical | C5 | ||
| Lirasacituzumab | Preclinical | PCSK9 | ||
| KAR-4717 | Preclinical | Nectin-4 | ||
| Zoritenlimab | Preclinical | CDK4/6 | ||
| Teracilimab | Phase 2/3 | TIGIT | ||
| XBI-1781 | Phase 3 | WRN | ||
| Fixaratamab | Phase 1/2 | PD-L1 | ||
| Teralucimab | Approved | SMN2 | ||
| IMM-2816 | Approved | Cl18.2 | ||
| DMA-2916 | Phase 1/2 | CD38 | ||
| Elrafotisoran | Phase 3 | FLT3 | ||
| Pemifutibatinib | Phase 2/3 | IL-13 | ||
| Adagrainavolisib | Phase 2/3 | FcRn | ||
| Tezezasiran | Phase 2 | PRMT5 | ||
| Surazumab | Preclinical | FLT3 | ||
| GLT-1490 | Phase 1 | Nectin-4 | ||
| SHI-2989 | Phase 2 | AHR | ||
| Zanufotisoran | Approved | BET | ||
| Nidazumab | Phase 1/2 | KRASG12C | ||
| Ivozasiran | Phase 3 | CFTR | ||
| NOR-4666 | Phase 3 | IL-13 | ||
| AMB-7870 | Phase 3 | IL-13 | ||
| IMM-5834 | Phase 2 | FGFR | ||
| Talazasiran | Approved | PLK4 | ||
| ACL-6459 | Phase 3 | FGFR | ||
| Ivoratamab | Phase 2/3 | Tau | ||
| Lisozasiran | NDA/BLA | IL-17A | ||
| Mirisertib | Phase 3 | CD19 | ||
| Sovazumab | Phase 1 | IL-13 | ||
| 418-6056 | Phase 1/2 | BCL-2 | ||
| Nidacilimab | Approved | JAK2 | ||
| Nidarelsin | Approved | FGFR | ||
| MRK-7986 | Phase 1/2 | WRN | ||
| Tirazumab | Phase 2/3 | KIF18A | ||
| TXM-5550 | NDA/BLA | KRASG12C | ||
| Fixabrutinib | Phase 1 | MET | ||
| Pexasertib | Approved | MET | ||
| Terarelsin | Phase 1/2 | TIGIT | ||
| Ivonesiran | Phase 1/2 | CGRP | ||
| Gozesertib | Phase 1/2 | CDK2 | ||
| Talafutibatinib | Phase 3 | TROP-2 | ||
| Surasertib | Phase 1/2 | CGRP | ||
| ZYD-981 | Preclinical | TIGIT | ||
| BIO-1735 | Phase 2 | Cl18.2 | ||
| 300-8538 | NDA/BLA | PLK4 | ||
| Rimamavacamten | Preclinical | GPRC5D | ||
| RGE-6554 | Phase 1 | SMN2 | ||
| WST-3903 | Preclinical | FXIa | ||
| DEC-8558 | Preclinical | Cl18.2 | ||
| NEO-8617 | Phase 1/2 | CD3 |
Trials (66)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08045492 | VRT-9481 | Phase 1/2 | Terminated |
| NCT04680525 | SLR-5251 | Phase 3 | Terminated |
| NCT05501447 | Talainavolisib | Approved | Recruiting |
| NCT07816425 | Talainavolisib | Approved | Active |
| NCT07555894 | PEK-IIT-463 | Preclinical | Completed |
| NCT08650235 | DUK-IIT-841 | Phase 1 | Recruiting |
| NCT08271356 | Tixaglumide | Preclinical | Active |
| NCT07366269 | KAR-4717 | Preclinical | Active |
| NCT05064970 | KAR-4717 | Preclinical | Completed |
| NCT08250767 | Zoritenlimab | Preclinical | Completed |
| NCT04103386 | XBI-1781 | Phase 3 | Terminated |
| NCT06260699 | XBI-1781 | Phase 3 | Completed |
| NCT06797973 | XBI-1781 | Phase 3 | Terminated |
| NCT06163185 | Fixaratamab | Phase 1/2 | Completed |
| NCT03953076 | Teralucimab | Approved | Completed |
| NCT06815771 | IMM-2816 | Approved | Completed |
| NCT06450807 | DMA-2916 | Phase 1/2 | Recruiting |
| NCT05314823 | DMA-2916 | Phase 1/2 | Active |
| NCT07296031 | Elrafotisoran | Phase 3 | Active |
| NCT05745977 | Elrafotisoran | Phase 3 | Not yet recr... |